Dietary lipids and Alzheimer's disease

Current Alzheimer Research

Volumn 10, Issue 5, 2013, Pages 542-548

  Amtul, Zareen ^a,e   Park, Jae Wook ^a   Murphy, M Paul ^b   Siddiqui, Rafat A ^c,d   Choudhary, Muhammad Iqbal ^e  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF KENTUCKY   (United States)

^c INDIANA UNIVERSITY   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

Alzheimer's disease; Diet; Experimental design; Lipids

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; FATTY ACID; LIPID; SATURATED FATTY ACID;

ALZHEIMER DISEASE; ARTICLE; CLINICAL EXAMINATION; COGNITIVE DEFECT; FAT INTAKE; HEAD INJURY; IN VITRO STUDY; IN VIVO STUDY; LIPID ABSORPTION; LIPID DIET; LIPID METABOLISM; LIPID OXIDATION; MEDICAL RESEARCH; NEUROPATHOLOGY; NUTRIENT; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; TISSUE CULTURE; TRANSGENE; TRAUMATIC BRAIN INJURY;

ALZHEIMER DISEASE; ANIMALS; BRAIN; COGNITION DISORDERS; DIETARY FATS; HUMANS;

EID: 84888234860     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011310050010     Document Type: Article

References (71)

1. Davidson EA, Robertson EE. Alzheimer's disease with acne ro-sacea in one of identical twins. J Neurol Neurosurg Psychiatry 18(1): 72-77 (1955).
2. Gatz M, Pedersen NL, Berg S, Johansson B, Johansson K, Mortimer JA, et al. Heritability for Alzheimer's disease: the study of dementia in Swedish twins. J Gerontol A Biol Sci Med Sci 52(2): M117-M125 (1997).
3. Hendrie HC, Osuntokun BO, Hall KS, Ogunniyi AO, Hui SL, Unverzagt FW, et al. Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. Am J Psychiatry 152(10): 1485-1492 (1995).
4. Graves AB, Larson EB, Edland SD, Bowen JD, McCormick WC, McCurry SM, et al. Prevalence of dementia and its subtypes in the Japanese American population of King County, Washington state. The Kame Project. Am J Epidemiol 144(8): 760-771 (1996).
5. White L, Petrovitch H, Ross GW, Masaki KH, Abbott RD, Teng EL, et al. Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging Study. JAMA 276(12): 955-960 (1996).
6. Kalaria RN. Small vessel disease and Alzheimer's dementia: pathological considerations. Cerebrovasc Dis 13(2): 48-52 (2002).
7. Foley P. Lipids in Alzheimer's disease: A century-old story. Bio-chim Biophys Acta 2010; 1801(8):750-753.
8. A. Alzheimer. Über eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift für Psychiatrie und psychisch-gerichtliche Medizin 64: 146-148 (1907).
9. Grant WB. Dietary links to Alzheimer's disease: 1999 update. J Alzheimers Dis 1(4-5): 197-201 (1999).
10. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 42(5): 776-782 (1997).
11. Petot GJ, Friedland RP. Lipids, diet and Alzheimer disease: an extended summary. J Neurol Sci 226(1-2):31-33 (2004).
12. Levin-Allerhand JA, Lominska CE, Smith JD. Increased amyloid-levels in APPSWE transgenic mice treated chronically with a physiological high-fat high-cholesterol diet. J Nutr Health Aging 6(5): 315-319 (2002).
13. Qin W, Chachich M, Lane M, Roth G, Bryant M, de CR, et al. Calorie restriction attenuates Alzheimer's disease type brain amy-loidosis in Squirrel monkeys (Saimiri sciureus). J Alzheimers Dis 10(4): 417-422 (2006).
14. Wang J, Ho L, Qin W, Rocher AB, Seror I, Humala N, et al. Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J 19(6): 659-661 (2005).
15. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274(5284): 99-102 (1996).
16. Grimm MO, Rothhaar TL, Hartmann T. The role of APP prote-olytic processing in lipid metabolism. Exp Brain Res (2011).
17. Miller DL, Papayannopoulos IA, Styles J, Bobin SA, Lin YY, Biemann K, et al. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys 301(1):41-52 (1993).
18. Selkoe DJ. Cell biology of the beta-amyloid precursor protein and the genetics of Alzheimer's disease. Cold Spring Harb Symp Quant Biol 61: 587-96 (1996).
19. Eckert GP, Cairns NJ, Maras A, Gattaz WF, Muller WE. Cholesterol modulates the membrane-disordering effects of beta-amyloid peptides in the hippocampus: specific changes in Alzheimer's disease. Dement Geriatr Cogn Disord 11(4): 181-186 (2000).
20. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18(7): 902-4 (2004).
21. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 12(7): 856-861 (2006).
22. Nishida Y, Ito S, Ohtsuki S, Yamamoto N, Takahashi T, Iwata N, et al. Depletion of vitamin E increases amyloid beta accumulation by decreasing its clearances from brain and blood in a mouse model of Alzheimer disease. J Biol Chem 284(48): 33400-33408 (2009).
23. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 43(5): 436-441 (2011).
24. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90(5): 1977-1981 (1993).
25. Gatz M, Reynolds CA, Finkel D, Pedersen NL, Walters E. Dementia in Swedish twins: predicting incident cases. Behav Genet 40(6): 768-775 (2010).
26. Sivanandam TM, Thakur MK. Traumatic brain injury: a risk factor for Alzheimer's disease. Neurosci Biobehav Rev 36(5):1376-1381 (2012).
27. Mayeux R, Ottman R, Maestre G, Ngai C, Tang MX, Ginsberg H, et al. Synergistic effects of traumatic head injury and apolipopro-tein-epsilon 4 in patients with Alzheimer's disease. Neurology 45(3 Pt 1): 555-557 (1995).
28. Lauritzen L, Hansen HS, Jorgensen MH, Michaelsen KF. The essentiality of long chain n-3 fatty acids in relation to development and function of the brain and retina. Prog Lipid Res 40(1-2): 1-94 (2001).
29. Yehuda S, Rabinovitz S, Mostofsky DI. Essential fatty acids are mediators of brain biochemistry and cognitive functions. J Neuro-sci Res 56(6): 565-570 (1999).
30. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 63(10):1402-1408 (2006).
31. Wolozin B. Cholesterol and the biology of Alzheimer's disease. Neuron 41(1): 7-10 (2004).
32. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van DC, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 304(17):1903-1911 (2010).
33. Pitt J, Roth W, Lacor P, Smith AB, III, Blankenship M, Velasco P, et al. Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleo-canthal. Toxicol Appl Pharmacol 240(2): 189-197(2009).
34. Calabrese V, Guagliano E, Sapienza M, Panebianco M, Calafato S, Puleo E, et al. Redox regulation of cellular stress response in aging and neurodegenerative disorders: role of vitagenes. Neurochem Res 32(4-5):757-773 (2007).
35. Scarmeas N, Stern Y, Mayeux R, Luchsinger JA. Mediterranean diet, Alzheimer disease, and vascular mediation. Arch Neurol 63(12):1709-1717 (2006).
36. Scarmeas N, Stern Y, Tang MX, Mayeux R, Luchsinger JA. Mediterranean diet and risk for Alzheimer's disease. Ann Neurol 59(6): 912-21 (2006).
37. Scarmeas N, Luchsinger JA, Mayeux R, Stern Y. Mediterranean diet and Alzheimer disease mortality. Neurology 69(11):1084-1093 (2007).
38. Oksman M, Iivonen H, Hogyes E, Amtul Z, Penke B, Leenders I, et al. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 23(3): 563-572 (2006).
39. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 164(2): 361-369 (2002).
40. Amtul Z, Keet M, Wang L, Merrifield P, Westaway D, Rozmahel RF. DHA supplemented in peptamen diet offers no advantage in pathways to amyloidosis: is it time to evaluate composite lipid diet? PLoS One 6(9): e24094 (2011).
41. Amtul Z, Uhrig M, Beyreuther K. Additive effects of fatty acid mixtures on the levels and ratio of amyloid beta40/42 peptides differ from the effects of individual fatty acids. J Neurosci Res 89(11): 1795-1801 (2011).
42. Gu Y, Nieves JW, Stern Y, Luchsinger JA, Scarmeas N. Food combination and Alzheimer disease risk: a protective diet. Arch Neurol 67(6): 699-706 (2010).
43. Green KN, Martinez-Coria H, Khashwji H, Hall EB, Yurko-Mauro KA, Ellis L, et al. Dietary docosahexaenoic acid and docosapen-taenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci 27(16): 4385-4395 (2007).
44. Hashimoto M, Hossain S, Agdul H, Shido O. Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid beta-infused rats relates to the decreases of amyloid beta and cholesterol levels in detergent-insoluble membrane fractions. Biochim Biophys Acta 1738(1-3): 91-8 (2005).
45. Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neu-rosci 25(12): 3032-3040 (2005).
46. Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 63(11): 1545-1550 (2006).
47. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 276(24): 21562-70 (2001).
48. Singh M, Nam DT, Arseneault M, Ramassamy C. Role of byproducts of lipid oxidation in Alzheimer's disease brain: a focus on acrolein. J Alzheimers Dis 21(3): 741-756 (2010).
49. Wang YH, Leibholz J, Bryden WL, Fraser DR. Lipid peroxidation status as an index to evaluate the influence of dietary fats on vitamin E requirements of young pigs. Br J Nutr 75(1): 81-95 (1996).
50. Tamagno E, Parola M, Bardini P, Piccini A, Borghi R, Guglielmot-to M et al. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. J Neurochem 92(3): 628-636 (2005).
51. Cole SL, Vassar R. The Alzheimer's disease beta-secretase enzyme, BACE1. Mol Neurodegener 2:22 (2007).
52. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intra-cellular domain in vivo. Proc Natl Acad Sci U S A 100(7): 4162-4167 (2003).
53. Patil S, Chan C. Palmitic and stearic fatty acids induce Alzheimerlike hyperphosphorylation of tau in primary rat cortical neurons. Neurosci Lett 384(3): 288-93 (2005).
54. Patil S, Melrose J, Chan C. Involvement of astroglial ceramide in palmitic acid-induced Alzheimer-like changes in primary neurons. Eur J Neurosci 26(8): 2131-2141 (2007).
55. Blazquez C, Galve-Roperh I, Guzman M. De novo-synthesized ceramide signals apoptosis in astrocytes via extracellular signal-regulated kinase. FASEB J 14(14): 2315-2322 (2000).
56. Patil S, Balu D, Melrose J, Chan C. Brain region-specificity of palmitic acid-induced abnormalities associated with Alzheimer's disease. BMC Res Notes 1: 20 (2008).
57. Chen Y, Ginis I, Hallenbeck JM. The protective effect of ceramide in immature rat brain hypoxia-ischemia involves up-regulation of bcl-2 and reduction of TUNEL-positive cells. J Cereb Blood Flow Metab 21(1): 34-40 (2001).
58. Han X, Holtzman M, McKeel DW, Jr., Kelley J, Morris JC. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neu-rochem 82(4): 809-818 (2002).
59. Pei Z, Oey NA, Zuidervaart MM, Jia Z, Li Y, Steinberg SJ, et al. The acyl-CoA synthetase bubblegum (lipidosin): further charac-terization and role in neuronal fatty acid beta-oxidation. J Biol Chem 278(47): 47070-47078 (2003).
60. Szutowicz A, Lysiak W. Regional and subcellular distribution of ATP-citrate lyase and other enzymes of acetyl-CoA metabolism in rat brain. J Neurochem 35(4): 775-785 (1980).
61. Sampath H, Ntambi JM. The fate and intermediary metabolism of stearic acid. Lipids 40(12): 1187-1191 (2005).
62. Bonanome A, Grundy SM. Effect of dietary stearic acid on plasma cholesterol and lipoprotein levels. N Engl J Med 318(19): 1244-1248 (1988).
63. Dougherty RM, Allman MA, Iacono JM. Effects of diets containing high or low amounts of stearic acid on plasma lipoprotein fractions and fecal fatty acid excretion of men. Am J Clin Nutr 61(5): 1120-1128 (1995).
64. Kritchevsky D. Stearic acid metabolism and atherogenesis: history. Am J Clin Nutr 60(6): 997S-1001S (1994).
65. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322(7300):1447-51 (2001).
66. Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 37(2): 268-285 (1985).
67. Clark AJ, Bissinger P, Bullock DW, Damak S, Wallace R, White-law CB, et al. Chromosomal position effects and the modulation of transgene expression. Reprod Fertil Dev 6(5): 589-598 (1994).
68. Clare L, Woods RT, Moniz Cook ED, Orrell M, Spector A. Cognitive rehabilitation and cognitive training for early-stage Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev (4): CD003260 (2003).
69. Schneider LS, Sano M. Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimers Dement 5(5): 388-397 (2009).
70. de la Torre JC. Cerebrovascular and cardiovascular pathology in Alzheimer's disease. Int Rev Neurobiol 84: 35-48 (2009).
71. Burgener SC, Buettner L, Coen BK, Beattie E, Bossen AL, Fick DM, et al. Evidence supporting nutritional interventions for persons in early stage Alzheimer's disease (AD). J Nutr Health Aging 12(1): 18-21 (2008).